Seroatlas · Human Serome Atlas

NCR1

Natural cytotoxicity triggering receptor 1

Also known as: CD335, LY94, NCTR1_HUMAN, NK-p46, NKP46

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O76036
Gene: NCR1
Ensembl: ENSG00000189430
Chromosome: 19
Canonical length: 304 aa
Protein class: CD markers, Predicted membrane proteins

OverviewNCBI Gene

Predicted to be involved in immune response-regulating signaling pathway. Predicted to act upstream of or within defense response to virus and detection of virus. Predicted to be located in cell surface. Predicted to be part of SWI/SNF complex. Predicted to be active in plasma membrane. Biomarker of acquired immunodeficiency syndrome; anogenital venereal wart; hepatitis C; and lymphoproliferative syndrome. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

304 residues, UniProt reviewed canonical sequence.

>O76036|NCR1
     1  MSSTLPALLC VGLCLSQRIS AQQQTLPKPF IWAEPHFMVP KEKQVTICCQ GNYGAVEYQL
    61  HFEGSLFAVD RPKPPERINK VQFYIPDMNS RMAGQYSCIY RVGELWSEPS NLLDLVVTEM
   121  YDTPTLSVHP GPEVISGEKV TFYCRLDTAT SMFLLLKEGR SSHVQRGYGK VQAEFPLGPV
   181  TTAHRGTYRC FGSYNNHAWS FPSEPVKLLV TGDIENTSLA PEDPTFPADT WGTYLLTTET
   241  GLQKDHALWD HTAQNLLRMG LAFLVLVALV WFLVEDWLSR KRTRERASRA STWEGRRRLN
   301  TQTL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NCR1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.39
Highest tissue expression: 3.3 nTPM

Expression across tissuesHPA

Tissue

spleen: 3.3 nTPM
lung: 0.8 nTPM
bone marrow: 0.7 nTPM
liver: 0.5 nTPM
adipose tissue: 0.2 nTPM
appendix: 0.2 nTPM

Single-cell type

nk-cells: 24 nCPM
innate lymphoid cells: 1 nCPM
t-cells: 0.9 nCPM
microglia: 0.5 nCPM
monocytes: 0.3 nCPM
megakaryocyte-erythroid progenitors: 0.2 nCPM

Immune cell

NK-cell: 1.1 nTPM
gdT-cell: 0.2 nTPM
basophil: 0.1 nTPM
total PBMC: 0.1 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM

Brain region

cerebral cortex: 2.4 nTPM
pons: 0.3 nTPM
basal ganglia: 0.2 nTPM
choroid plexus: 0.2 nTPM
hippocampal formation: 0.2 nTPM
hypothalamus: 0.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.45
gnomAD pLI: 0
gnomAD missense Z: -0.25
DepMap mean gene effect: -0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of NCR1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NCR1 as an antibody target. Whether an autoantibody or antibody against NCR1 could matter depends on whether native NCR1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NCR1 is annotated at the cell surface, where native NCR1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label NCR1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...